Quantitative Imaging and Dosimetry Solutions
We offer comprehensive services related to dosimetry for radiopharmaceutical development from imaging and dosimetry protocol development to FDA-ready report generation.
Comprehensive Centralized Image Analysis and Dosimetry Solutions
We offer comprehensive centralized dosimetry solutions for data acquired at one or more institutions participating in a multi-center trial of a radiopharmaceutical therapeutic or diagnostic agent.
- Support for a large number of radionuclides used in radiopharmaceutical diagnosis and therapy such as Tc-99m, I-123, In-111, Tl-201, I-131, Y-90, Lu-177, Ra-223, Th-227, Pb-212, Ac-225, and more.
- Centralized, quantitative vendor-independent reconstruction of SPECT/CT images.
- Guidance and advice on best practices for Nuclear Medicine image acquisition including the determination of the number of measurement time points for the radionuclide used, acquisition duration, choice of collimator and energy window settings, calibration, and multi-center standardization.
- Incorporated advanced compensation for NM image-quality degrading factors such as attenuation, scatter, down scatter, collimator-detector response, partial volume, count rate (dead time) losses, and more.
- Patient-specific Monte Carlo (MC) simulation-based tissue and tumor dosimetry.
- Centralized, quantitative vendor-independent reconstruction of SPECT/CT images.
- Standard phantom (CE and ICRP) normal tissue dosimetry.
Not sure what services are right for your project? Talk to our experts today. Learn More:
Professional Experience
Professional Experience
Dedicated Expert Full Time Staff
Dedicated Expert Full Time Staff
Real time process to start calculation
Real time process to start calculation
Talk to our experts and get tailored pricing for your project.
Professional Experience
Professional Experience
Dedicated Expert Full Time Staff
Dedicated Expert Full Time Staff
Expertise with quantitative imaging of diagnostic radionuclides including Tc-99m, I-123, In-111, and TI-201.
Expertise with quantitative imaging of therapeutic radionuclides including I-131, Sm-153, Y-90, Lu-177, Ra-223, Th-227, Pb-212, and Ac-225.
Real time process to start calculation
Real time process to start calculation
Image Acquisition
- Support for imaging trial design
- Number of imaging acquisition time-points
- Camera acquisition settings
- A detailed description of phantom studies to assure accuracy
- Imaging manual w/ SOPs
- Centralized vendor-agnostic quantitative SPECT imaging
Centralized Dosimetry
- Standard phantom and voxelized patient specific
- Normal organ and tumor dosimetry
- Diagnostic or therapeutic radionuclides
- Consistent with MIRD Committee and ICRP guidelines.
- Experts at incorporating special considerations associated with α-emitter dosimetry
Centralized Quantitative Reconstruction
- Methods that are independent of camera manufacturer
- Advanced compensation for scatter, downscatter, crosstalk from daughter radionuclides
- Advanced compensation for collimator response including septal penetration and scatter
- Advanced partial-volume compensation
- Experience with diagnostic radionuclides including Tc-99m, I-123, In-111, Tl-201
- Experience with therapeutic radionuclides including I-131, Y-90, Lu-177, Ra-223, Th-227, Pb-212
- Experience with therapeutic radionuclides including I-131, Y-90, Lu-177, Ra-223, Th-227, Pb-212
Radiobiological Analysis of Dosimetry Results
- Relate dosimetry to tumor control probability and to potential normal tissue toxicity (TCP, NTCP)
- Perform dose-rate adjustment to relate radiopharmaceutical doses to radiotherapy experience (BED, EQD2)
- Use of application-specific RBE value for α-particle emitters
Detailed, FDA-Ready Reports
- Exact description of methodology and results, including input data, assumptions used in the calculations
Comprehensive centralized imaging and dosimetry solutions for data acquired
We offer comprehensive centralized imaging and dosimetry solutions for data acquired at one or more institutions participating in a multi-center trial of a radiopharmaceutical therapeutic or diagnostic agent.
- Support for a large number of radionuclides used in radiopharmaceutical diagnosis and therapy such as Tc-99m, I-123, In-111, Tl-201, I-131, Y-90, Lu-177, Ra-223, Th-227, Pb-212, Ac-225, and more.
- Centralized, quantitative vendor-independent reconstruction of SPECT/CT images.
- Guidance and advice on best practices for Nuclear Medicine image acquisition including the determination of the number of measurement time points for the radionuclide used, acquisition duration, choice of collimator and energy window settings, calibration, and multi-center standardization.
- Incorporated advanced compensation for NM image-quality degrading factors such as attenuation, scatter, down scatter, collimator-detector response, partial volume, count rate (dead time) losses, and more.
- Patient-specific Monte Carlo (MC) simulation-based tissue and tumor dosimetry.
- Centralized, quantitative vendor-independent reconstruction of SPECT/CT images.
- Standard phantom (CE and ICRP) normal tissue dosimetry.
Talk to our experts and get tailored pricing for your project.